SCHEMBL712663

SCHEMBL712663

O=S(=O)(Nc1nccs1)c1ccc(Nc2nc(Cc3ccc(Cl)cc3)cs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
PPIA P62937 1/20 0.57
SCN9A Q15858 5/20 0.54
SCN3A Q9NY46 2/20 0.52
SCN5A Q14524 1/20 0.52
ALOX12 P18054 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CCNT1 O60563 1/20 0.50
CDK9 P50750 1/20 0.50
AVPR2 P30518 1/20 0.49
GPR27 Q9NS67 1/20 0.49
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP2C9 P11712 1/20 0.47
EDNRA P25101 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714319 0.89 LMNA (0.58) LMNASMN1; SMN2PPIASCN9ASCN3A
SCHEMBL713152 0.87 LMNA (0.56) LMNASMN1; SMN2PPIASCN9ASCN3A
SCHEMBL713129 0.86 LMNA (0.60) LMNASMN1; SMN2PPIASCN9ASCN3A
SCHEMBL713939 0.85 SCN9A (0.70) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL711820 0.84 KDM4E (0.58) LMNASMN1; SMN2ALOX12MEN1KMT2A
SCHEMBL711721 0.84 LMNA (0.56) LMNASMN1; SMN2PPIASCN9ASCN3A
SCHEMBL714308 0.83 KMT2A (0.51) SMN1; SMN2MEN1KMT2AHTTALDH1A1
SCHEMBL713208 0.82 ADRB2 (0.57) LMNASMN1; SMN2PPIASCN3ASCN5A
SCHEMBL714291 0.82 LMNA (0.60) LMNASMN1; SMN2PPIASCN9ASCN3A
SCHEMBL712587 0.82 LMNA (0.62) LMNASMN1; SMN2PPIASCN9ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A LMNA 2921/4885SMN1; SMN2 287/4885PPIA 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.